Designing inhibitors of anthrax toxin

Expert Opinion on Drug Discovery

Volumn 9, Issue 3, 2014, Pages 299-318

  Nestorovich, Ekaterina M ^a   Bezrukov, Sergey M ^b  

^a CATHOLIC UNIVERSITY OF AMERICA   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Antitoxins; Bacillus anthracis; Binary toxins; Polyvalent interactions; Rational drug design

Indexed keywords

[1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; ANTHRAX TOXIN; ANTHRAX VACCINE; ANTITOXIN; CELL SURFACE RECEPTOR; CIPROFLOXACIN; FURIN; GLYCOPROTEIN; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PA 63 PROTEIN; PSEUDOMONAS EXOTOXIN; RAXIBACUMAB; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTHRAX; BACILLUS ANTHRACIS; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; BIOLOGICAL WARFARE; CHEMICAL STRUCTURE; DRUG APPROVAL; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; EDEMA; ENDOCYTOSIS; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; INTRACELLULAR TRANSPORT; LETHAL GENE; LETHALITY; LIPID BILAYER; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, BACTERIAL; ANTITOXINS; BACILLUS ANTHRACIS; BACTERIAL TOXINS; DRUG DESIGN; HUMANS;

EID: 84896728807     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.877884     Document Type: Review

References (162)

1. Ravina E. The evolution of drug discovery: From traditional medicines to modern drugs. Wiley-VCH, Weinheim, Germany; 2011
2. Krogsgaard-Larsen P, Stromgaard K, Madsen U. Drug design and discovery. CRC Press Taylor & Francis Group, New York, USA; 2010
3. Schneider G, Baringhaus K. Molecular design: Concepts and applications. Wiley-VCH, Weinheim, Germany; 2008
4. Bouzianas DG. Medical countermeasures to protect humans from anthrax bioterrorism. Trends Microbiol 2009;17:522-8
5. Chen Z, Moayeri M, Purcell R. Monoclonal antibody therapies against anthrax. Toxins (Basel) 2011;3:1004-19
6. Beierlein JM, Anderson AC. New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for bacillus anthracis. Curr Med Chem 2011;18:5083-94
7. Bouzianas DG. Current and future medical approaches to combat the anthrax threat. J Med Chem 2010;53:4305-31
8. Artenstein AW, Opal SM. Novel approaches to the treatment of systemic anthrax. Clin Infect Dis 2012;54:1148-61
9. Fouet A. The surface of bacillus anthracis. Mol Aspects Med 2009;30:374-85
10. Young JA, Collier RJ. Anthrax toxin: Receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007;76:243-65
11. Moayeri M, Leppla SH. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med 2009;30:439-55
12. Barth H, Aktories K, Popoff MR, et al. Binary bacterial toxins: Biochemistry, biology, and applications of common clostridium and bacillus proteins. Microbiol Mol Biol Rev 2004;68:373-402
13. Petosa C, Collier RJ, Klimpel KR, et al. Crystal structure of the anthrax toxin protective antigen. Nature 1997;385:833-8
14. Kintzer AF, Thoren KL, Sterling HJ, et al. The protective antigen component of anthrax toxin forms functional octameric complexes. J Mol Biol 2009;392:614-29
15. Mogridge J, Cunningham K, Collier RJ. Stoichiometry of anthrax toxin complexes. Biochemistry 2002;41:1079-82
16. Pilpa RM, Bayrhuber M, Marlett JM, et al. A receptor-based switch that regulates anthrax toxin pore formation. PLoS Pathog 2011;7:e1002354
17. Blaustein RO, Koehler TM, Collier RJ, et al. Anthrax toxin: Channel-forming activity of protective antigen in planar phospholipid bilayers. Proc Natl Acad Sci USA 1989;86:2209-13
18. Katayama H, Janowiak BE, Brzozowski M, et al. GroEL as a molecular scaffold for structural analysis of the anthrax toxin pore. Nat Struct Mol Biol 2008;15:754-60
19. Zhang S, Udho E, Wu Z, et al. Protein translocation through anthrax toxin channels formed in planar lipid bilayers. Biophys J 2004;87:3842-9
20. Zhang S, Finkelstein A, Collier RJ. Evidence that translocation of anthrax toxin?s lethal factor is initiated by entry of its N terminus into the protective antigen channel. Proc Natl Acad Sci USA 2004;101:16756-61
21. Krantz BA, Melnyk RA, Zhang S, et al. A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science 2005;309:777-81
22. Basilio D, Juris SJ, Collier RJ, et al. Evidence for a proton-protein symport mechanism in the anthrax toxin channel. J Gen Physiol 2009;133:307-14
23. Basilio D, Kienker PK, Briggs SW, et al. A kinetic analysis of protein transport through the anthrax toxin channel. J Gen Physiol 2011;137:521-31
24. Basilio D, Jennings-Antipov LD, Jakes KS, et al. Trapping a translocating protein within the anthrax toxin channel: Implications for the secondary structure of permeating proteins. J Gen Physiol 2011;137:343-56
25. Janowiak BE, Finkelstein A, Collier RJ. An approach to characterizing singlesubunit mutations in multimeric prepores and pores of anthrax protective antigen. Protein Sci 2009;18:348-58
26. Thoren KL, Worden EJ, Yassif JM, et al. Lethal factor unfolding is the most forcedependent step of anthrax toxin translocation. Proc Natl Acad Sci USA 2009;106:21555-60
27. Pentelute BL, Sharma O, Collier RJ. Chemical dissection of protein translocation through the anthrax toxin pore. Angew Chem Int Ed Engl 2011;50:2294-6
28. Feld GK, Brown MJ, Krantz BA. Ratcheting up protein translocation with anthrax toxin. Protein Sci 2012;21:606-24
29. Brown MJ, Thoren KL, Krantz BA. Charge requirements for proton gradientdriven translocation of anthrax toxin. J Biol Chem 2011;286:23189-99
30. Krantz BA, Finkelstein A, Collier RJ. Protein translocation through the anthrax toxin transmembrane pore is driven by a proton gradient. J Mol Biol 2006;355:968-79
31. Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998;280:734-7
32. Vitale G, Bernardi L, Napolitani G, et al. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J 2000;352(Pt 3):739-45
33. Levinsohn JL, Newman ZL, Hellmich KA, et al. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog 2012;8:e1002638
34. Leppla SH. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982;79:3162-6
35. Dumetz F, Jouvion G, Khun H, et al. Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am J Pathol 2011;178:2523-35
36. Leysath CE, Chen KH, Moayeri M, et al. Mouse monoclonal antibodies to anthrax edema factor protect against infection. Infect Immun 2011;79:4609-16
37. Liu S, Zhang Y, Moayeri M, et al. Key tissue targets responsible for anthrax-toxin-induced lethality. Nature 2013;501:63-8
38. Guarner J, Jernigan JA, Shieh WJ, et al. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 2003;163:701-9
39. Nigrovic LE, Thompson KM. The lyme vaccine: A cautionary tale. Epidemiol Infect 2007;135:1-8
40. Jang KH, Nam SJ, Locke JB, et al. Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete. Angew Chem Int Ed Engl 2013;52:7822-4
41. Bouzianas DG. Potential biological targets of bacillus anthracis in antiinfective approaches against the threat of bioterrorism. Expert Rev Anti Infect Ther 2007;5:665-84
42. Bartlett JG, Inglesby TV Jr, Borio L. Management of anthrax. Clin Infect Dis 2002;35:851-8
43. Bull JJ, Parrish CR. Microbiology. A binding contract for anthrax. Science 2002;297:201-2
44. Mock M, Fouet A. Anthrax. Annu Rev Microbiol 2001;55:647-71
45. Gilligan PH. Therapeutic challenges posed by bacterial bioterrorism threats. Curr Opin Microbiol 2002;5:489-95
46. Rainey GJ, Young JA. Antitoxins: Novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2004;2:721-6
47. Friedlander AM. Tackling anthrax. Nature 2001;414:160-1
48. Fox JL. Anthrax drug first antibacterial mAb to win approval. Nat Biotechnol 2013;31:8
49. Russell L, Pedersen M, Jensen AV, et al. Two anthrax cases with soft tissue infection, severe oedema and sepsis in danish heroin users. BMC Infect Dis 2013;13:408
50. Bradley KA, Mogridge J, Mourez M, et al. Identification of the cellular receptor for anthrax toxin. Nature 2001;414:225-9
51. Scobie HM, Rainey GJ, Bradley KA, et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA 2003;100:5170-4
52. Martchenko M, Jeong SY, Cohen SN. Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc Natl Acad Sci USA 2010;107:15583-8
53. Little SF, Leppla SH, Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of bacillus anthracis toxin. Infect Immun 1988;56:1807-13
54. Bann JG, Cegelski L, Hultgren SJ. LRP6 holds the key to the entry of anthrax toxin. Cell 2006;124:1119-21
55. Basha S, Rai P, Poon V, et al. Polyvalent inhibitors of anthrax toxin that target host receptors. Proc Natl Acad Sci USA 2006;103:13509-13
56. Cai C, Che J, Xu L, et al. Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors. PLoS One 2011;6:e20646
57. Rogers MS, Cryan LM, Habeshian KA, et al. A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. PLoS One 2012;7:e39911
58. Cryan LM, Habeshian KA, Caldwell TP, et al. Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay. J Biomol Screen 2013;18:714-25
59. Cryan LM, Rogers MS. Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed) 2011;16:1574-88
60. Sarac MS, Peinado JR, Leppla SH, et al. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect Immun 2004;72:602-5
61. Kacprzak MM, Peinado JR, Than ME, et al. Inhibition of furin by polyargininecontaining peptides: Nanomolar inhibition by nona-D-arginine. J Biol Chem 2004;279:36788-94
62. Tonello F, Seveso M, Marin O, et al. Screening inhibitors of anthrax lethal factor. Nature 2002;418:386
63. Turk BE, Wong TY, Schwarzenbacher R, et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat Struct Mol Biol 2004;11:60-6
64. Peinado JR, Kacprzak MM, Leppla SH, et al. Cross-inhibition between furin and lethal factor inhibitors. Biochem Biophys Res Commun 2004;321:601-5
65. Shiryaev SA, Remacle AG, Ratnikov BI, et al. Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 2007;282:20847-53
66. Remacle AG, Gawlik K, Golubkov VS, et al. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol 2010;42:987-95
67. Opal SM, Artenstein AW, Cristofaro PA, et al. Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication. Infect Immun 2005;73:5101-5
68. Opal SM, Lim YP, Cristofaro P, et al. Inter-alpha inhibitor proteins: A novel therapeutic strategy for experimental anthrax infection. Shock 2011;35:42-4
69. Worachartcheewan A, Nantasenamat C, Naenna T, et al. Modeling the activity of furin inhibitors using artificial neural network. Eur J Med Chem 2009;44:1664-73
70. Moayeri M, Wiggins JF, Lindeman RE, et al. Cisplatin inhibition of anthrax lethal toxin. Antimicrob Agents Chemother 2006;50:2658-65
71. Rubert Perez C, Lopez-Perez D, Chmielewski J, et al. Small molecule inhibitors of anthrax toxin-induced cytotoxicity targeted against protective antigen. Chem Biol Drug Des 2012;79:260-9
72. Wein AN, Williams BN, Liu S, et al. Small molecule inhibitors of bacillus anthracis protective antigen proteolytic activation and oligomerization. J Med Chem 2012;55:7998-8006
73. Mourez M, Kane RS, Mogridge J, et al. Designing a polyvalent inhibitor of anthrax toxin. Nat Biotechnol 2001;19:958-61
74. Gujraty K, Sadacharan S, Frost M, et al. Functional characterization of peptidebased anthrax toxin inhibitors. Mol Pharm 2005;2:367-72
75. Rai P, Padala C, Poon V, et al. Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat Biotechnol 2006;24:582-6
76. Gujraty KV, Joshi A, Saraph A, et al. Synthesis of polyvalent inhibitors of controlled molecular weight: Structureactivity relationship for inhibitors of anthrax toxin. Biomacromolecules 2006;7:2082-5
77. Gujraty KV, Yanjarappa MJ, Saraph A, et al. Synthesis of homopolymers and copolymers containing an active ester of acrylic acid by RAFT: Scaffolds for controlling polyvalent ligand display. J Polym Sci A Polym Chem 2008;46:7246-57
78. Rai PR, Saraph A, Ashton R, et al. Raftlike polyvalent inhibitors of the anthrax toxin: Modulating inhibitory potency by formation of lipid microdomains. Angew Chem Int Ed Engl 2007;46:2207-9
79. Vance D, Shah M, Joshi A, et al. Polyvalency: A promising strategy for drug design. Biotechnol Bioeng 2008;101:429-34
80. Joshi A, Kate S, Poon V, et al. Structure-based design of a heptavalent anthrax toxin inhibitor. Biomacromolecules 2011;12:791-6
81. Karginov VA, Nestorovich EM, Moayeri M, et al. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc Natl Acad Sci USA 2005;102:15075-80
82. Abrami L, Kunz B, Van der Goot FG. Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake. Proc Natl Acad Sci USA 2010;107:1420-4
83. Abrami L, Bischofberger M, Kunz B, et al. Endocytosis of the anthrax toxin is mediated by clathrin, actin and unconventional adaptors. PLoS Pathog 2010;6:e1000792
84. Jeong SY, Martchenko M, Cohen SN. Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis. Proc Natl Acad Sci USA 2013;110:E4007-15
85. Gillespie EJ, Ho CL, Balaji K, et al. Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci USA 2013;110:E4904-12
86. Bann JG. Anthrax toxin protective antigen-insights into molecular switching from prepore to pore. Protein Sci 2012;21:1-12
87. Zhu PJ, Hobson JP, Southall N, et al. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorg Med Chem 2009;17:5139-45
88. Hobson JP, Liu S, Rono B, et al. Imaging specific cell-surface proteolytic activity in single living cells. Nat Methods 2006;3:259-61
89. Rosenfeld R, Marcus H, Ben-Arie E, et al. Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal bacillus anthracis infection. PLoS One 2009;4:e6351
90. Mechaly A, Levy H, Epstein E, et al. A novel mechanism for antibody-based anthrax toxin neutralization: Inhibition of prepore-to-pore conversion. J Biol Chem 2012;287:32665-73
91. Collier RJ. Membrane translocation by anthrax toxin. Mol Aspects Med 2009;30:413-22
92. Thoren KL, Krantz BA. The unfolding story of anthrax toxin translocation. Mol Microbiol 2011;80:588-95
93. Nablo BJ, Panchal RG, Bavari S, et al. Anthrax toxin-induced rupture of artificial lipid bilayer membranes. J Chem Phys 2013;139:065101
94. Sellman BR, Mourez M, Collier RJ. Dominant-negative mutants of a toxin subunit: An approach to therapy of anthrax. Science 2001;292:695-7
95. Singh Y, Khanna H, Chopra AP, et al. A dominant negative mutant of bacillus anthracis protective antigen inhibits anthrax toxin action in vivo. J Biol Chem 2001;276:22090-4
96. Yan M, Collier RJ. Characterization of dominant-negative forms of anthrax protective antigen. Mol Med 2003;9:46-51
97. Cao S, Guo A, Liu Z, et al. Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination. Infect Immun 2009;77:4679-87
98. Aulinger BA, Roehrl MH, Mekalanos JJ, et al. Combining anthrax vaccine and therapy: A dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 2005;73:3408-14
99. Janowiak BE, Fischer A, Collier RJ. Effects of introducing a single charged residue into the phenylalanine clamp of multimeric anthrax protective antigen. J Biol Chem 2010;285:8130-7
100. Sun J, Lang AE, Aktories K, et al. Phenylalanine-427 of anthrax protective antigen functions in both pore formation and protein translocation. Proc Natl Acad Sci USA 2008;105:4346-51
101. Montal M, Mueller P. Formation of bimolecular membranes from lipid monolayers and a study of their electrical properties. Proc Natl Acad Sci USA 1972;69:3561-6
102. Nestorovich EM, Bezrukov SM. Obstructing toxin pathways by targeted pore blockage. Chem Rev 2012;112(12):6388-430
103. Blaustein RO, Finkelstein A. Diffusion limitation in the block by symmetric tetraalkylammonium ions of anthrax toxin channels in planar phospholipid bilayer membranes. J Gen Physiol 1990;96:943-57
104. Blaustein RO, Finkelstein A. Voltage-dependent block of anthrax toxin channels in planar phospholipid bilayer membranes by symmetric tetraalkylammonium ions. Effects on macroscopic conductance. J Gen Physiol 1990;96:905-19
105. Blaustein RO, Lea EJ, Finkelstein A. Voltage-dependent block of anthrax toxin channels in planar phospholipid bilayer membranes by symmetric tetraalkylammonium ions. Single-channel analysis. J Gen Physiol 1990;96:921-42
106. Orlik F, Schiffler B, Benz R. Anthrax toxin protective antigen: Inhibition of channel function by chloroquine and related compounds and study of binding kinetics using the current noise analysis. Biophys J 2005;88:1715-24
107. Beitzinger C, Bronnhuber A, Duscha K, et al. Designed azolopyridinium salts block protective antigen pores in vitro and protect cells from anthrax toxin. PLoS One 2013;8:e66099
108. Karginov VA. Cyclodextrin derivatives as anti-infectives. Curr Opin Pharmacol 2013;13:717-25
109. Karginov VA, Nestorovich EM, Yohannes A, et al. Search for cyclodextrin-based inhibitors of anthrax toxins: Synthesis, structural features, and relative activities. Antimicrob Agents Chemother 2006;50:3740-53
110. Diaz-Moscoso A, Mendez-Ardoy A, Ortega-Caballero F, et al. Symmetry complementarity-guided design of anthrax toxin inhibitors based on betacyclodextrin: Synthesis and relative activities of face-selective functionalized polycationic clusters. ChemMedChem 2011;6:181-92
111. Yannakopoulou K, Jicsinszky L, Aggelidou C, et al. Symmetry requirements for effective blocking of pore-forming toxins: Comparative study with alpha-, beta-, and gammacyclodextrin derivatives. Antimicrob Agents Chemother 2011;55:3594-7
112. Moayeri M, Robinson TM, Leppla SH, et al. In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin. Antimicrob Agents Chemother 2008;52:2239-41
113. Dietrich PS, McGivern JG, Delgado SG, et al. Functional analysis of a voltagegated sodium channel and its splice variant from rat dorsal root ganglia. J Neurochem 1998;70:2262-72
114. Catterall WA, Perez-Reyes E, Snutch TP, et al. International union of pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005;57:411-25
115. Nestorovich EM, Karginov VA, Popoff MR, et al. Tailored sscyclodextrin blocks the translocation pores of binary exotoxins from C. botulinum and C. perfringens and protects cells from intoxication. PLoS One 2011;6:e23927
116. Bezrukov SM, Liu X, Karginov VA, et al. Interactions of high-affinity cationic blockers with the translocation pores of B. anthracis, C. botulinum, and C. perfringens binary toxins. Biophys J 2012;103:1208-17
117. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 1986;261:7123-6
118. Gordon VM, Leppla SH, Hewlett EL. Inhibitors of receptor-mediated endocytosis block the entry of bacillus anthracis adenylate cyclase toxin but not that of bordetella pertussis adenylate cyclase toxin. Infect Immun 1988;56:1066-9
119. Finkelstein A. The channel formed in planar lipid bilayers by the protective antigen component of anthrax toxin. Toxicology 1994;87:29-41
120. Dal Molin F, Tonello F, Ladant D, et al. Cell entry and cAMP imaging of anthrax edema toxin. EMBO J 2006;25:5405-13
121. Artenstein AW, Opal SM, Cristofaro P, et al. Chloroquine enhances survival in bacillus anthracis intoxication. J Infect Dis 2004;190:1655-60
122. Sanchez AM, Thomas D, Gillespie EJ, et al. Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother 2007;51:2403-11
123. Backer MV, Patel V, Jehning BT, et al. Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob Agents Chemother 2007;51:245-51
124. Moayeri M, Crown D, Jiao GS, et al. Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection. Antimicrob Agents Chemother 2013;57:4139-45
125. Abrami L, Brandi L, Moayeri M, et al. Hijacking multivesicular bodies enables long-term and exosome-mediated longdistance action of anthrax toxin. Cell Rep 2013;5(4):986-96
126. Montecucco C, Tonello F, Zanotti G. Stop the killer: How to inhibit the anthrax lethal factor metalloprotease. Trends Biochem Sci 2004;29:282-5
127. Dalkas GA, Papakyriakou A, Vlamis-Gardikas A, et al. Low molecular weight inhibitors of the protease anthrax lethal factor. Mini Rev Med Chem 2008;8:290-306
128. Turk BE. Discovery and development of anthrax lethal factor metalloproteinase inhibitors. Curr Pharm Biotechnol 2008;9:24-33
129. Tonello F, Montecucco C. The anthrax lethal factor and its MAPK kinasespecific metalloprotease activity. Mol Aspects Med 2009;30:431-8
130. Panchal RG, Hermone AR, Nguyen TL, et al. Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol 2004;11:67-72
131. Shoop WL, Xiong Y, Wiltsie J, et al. Anthrax lethal factor inhibition. Proc Natl Acad Sci USA 2005;102:7958-63
132. Goldman ME, Cregar L, Nguyen D, et al. Cationic polyamines inhibit anthrax lethal factor protease. BMC Pharmacol 2006;6:8
133. Kuzmic P, Cregar L, Millis SZ, et al. Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosides. FEBS J 2006;273:3054-62
134. Fridman M, Belakhov V, Lee LV, et al. Dual effect of synthetic aminoglycosides: Antibacterial activity against bacillus anthracis and inhibition of anthrax lethal factor. Angew Chem Int Ed Engl 2005;44:447-52
135. Kim C, Gajendran N, Mittrucker HW, et al. Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc Natl Acad Sci USA 2005;102:4830-5
136. Wang W, Mulakala C, Ward SC, et al. Retrocyclins kill bacilli and germinating spores of bacillus anthracis and inactivate anthrax lethal toxin. J Biol Chem 2006;281:32755-64
137. Wickliffe KE, Leppla SH, Moayeri M. Killing of macrophages by anthrax lethal toxin: Involvement of the N-end rule pathway. Cell Microbiol 2008;10:1352-62
138. Chiu TL, Amin EA. Development of a comprehensive, validated pharmacophore hypothesis for anthrax toxin lethal factor (LF) inhibitors using genetic algorithms, pareto scoring, and structural biology. J Chem Inf Model 2012;52:1886-97
139. Jiao GS, Kim S, Moayeri M, et al. Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy. Bioorg Med Chem Lett 2010;20:6850-3
140. Kim S, Jiao GS, Moayeri M, et al. Antidotes to anthrax lethal factor intoxication. Part 2: Structural modifications leading to improved in vivo efficacy. Bioorg Med Chem Lett 2011;21:2030-3
141. Jiao GS, Kim S, Moayeri M, et al. Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett 2012;22:2242-6
142. Sirard JC, Mock M, Fouet A. The three bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature. J Bacteriol 1994;176:5188-92
143. Mabry R, Brasky K, Geiger R, et al. Detection of anthrax toxin in the serum of animals infected with bacillus anthracis by using engineered immunoassays. Clin Vaccine Immunol 2006;13:671-7
144. Molin FD, Fasanella A, Simonato M, et al. Ratio of lethal and edema factors in rabbit systemic anthrax. Toxicon 2008;52:824-8
145. Laine E, Martinez L, Ladant D, et al. Molecular motions as a drug target: Mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors. Toxins (Basel) 2012;4:580-604
146. Schein CH, Chen D, Ma L, et al. Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor. Toxins (Basel) 2012;4:1288-300
147. Seifert R, Dove S. Inhibitors of bacillus anthracis edema factor. Pharmacol Ther 2013;140:200-12
148. Chen Z, Moayeri M, Zhao H, et al. Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci USA 2009;106:13487-92
149. Winterroth L, Rivera J, Nakouzi AS, et al. Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax. Infect Immun 2010;78:2890-8
150. Makiya M, Dolan M, Agulto L, et al. Structural basis of anthrax edema factor neutralization by a neutralizing antibody. Biochem Biophys Res Commun 2012;417:324-9
151. Soelaiman S, Wei BQ, Bergson P, et al. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem 2003;278:25990-7
152. Chen D, Misra M, Sower L, et al. Novel inhibitors of anthrax edema factor. Bioorg Med Chem 2008;16:7225-33
153. Laine E, Goncalves C, Karst JC, et al. Use of allostery to identify inhibitors of calmodulin-induced activation of bacillus anthracis edema factor. Proc Natl Acad Sci USA 2010;107:11277-82
154. Taha HM, Schmidt J, Gottle M, et al. Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2?(3?)-O-(N-(methyl) anthraniloyl)-substituted purine and pyrimidine nucleotides. Mol Pharmacol 2009;75:693-703
155. Taha H, Dove S, Geduhn J, et al. Inhibition of the adenylyl cyclase toxin, edema factor, from bacillus anthracis by a series of 18 mono-and bis-(M)ANTsubstituted nucleoside 5?-triphosphates. Naunyn Schmiedebergs Arch Pharmacol 2012;385:57-68
156. Shen Y, Zhukovskaya NL, Zimmer MI, et al. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:3242-7
157. Suryanarayana S, Wang JL, Richter M, et al. Distinct interactions of 2?-and 3?-O-(N-methyl)anthraniloyl-isomers of ATP and GTP with the adenylyl cyclase toxin of bacillus anthracis, edema factor. Biochem Pharmacol 2009;78:224-30
158. Pinto C, Lushington GH, Richter M, et al. Structure-activity relationships for the interactions of 2?-and 3?-(O)-(Nmethyl) anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases. Biochem Pharmacol 2011;82:358-70
159. Chen D, Ma L, Kanalas JJ, et al. Structure-based redesign of an edema toxin inhibitor. Bioorg Med Chem 2012;20:368-76
160. Dolgin E. Animal rule for drug approval creates a jungle of confusion. Nat Med 2013;19:118-19
161. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
162. Nestorovich EM, Karginov VA, Berezhkovskii AM, et al. Blockage of anthrax PA63 pore by a multicharged high-affinity toxin inhibitor. Biophys J 2010;99:134-43